Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
Telix is delighted to announce that Danielle Meyrick MD has joined its executive medical team in the role of Chief Medical Officer (CMO), Asia-Pacific.
Danielle is a practicing medical practitioner, holding an MD from the University of Western Australia and also has a PhD in radiopharmaceutical chemistry, having worked extensively in the synthesis and early clinical application of novel diagnostic and therapeutic radiopharmaceuticals.
Prior to joining Telix, Danielle held the position of Chief Scientist GenesisCare Theranostics and was instrumental in developing a Special Access clinical program and establishing a robust platform of research within the organisation. At GenesisCare, Danielle established a nuclear medicine dosimetry and central imaging service to support the Clinical CRO offering.
Danielle was previously Global Senior Innovation Technical Specialist at BASF and has held various senior positions in academia, including Deputy School Dean at the Faculty of Science and Engineering, Murdoch University, and Assoc. Professor at the School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia.
Danielle will lead Telix’s medical interactions in APAC, helping market development with regional medical affairs and strategic clinical activities; her appointment and experience in nuclear medicine provide a valuable addition to the Telix team.
We welcome Danielle to the organisation as we continue to grow our presence and develop our pipeline in the Asia-Pacific region.